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Respiratory syncytial virus prevention in children with 
congenital heart disease: who and how?
Respiratory syncytial virus (RSV) is a major cause of respiratory in-
fection in children. Most of the pediatric population have RSV infection 
before the age of 2, and recurrent infections are common even within 
one season. Chronic lung disease, prematurity, along with congenital 
heart disease (CHD) are major risk factors in severe lower respiratory 
infection. In hemo-dynamically significant CHD patients with RSV 
infection, hospitalization is usually needed and the possibility of 
treatment in intensive care unit and the use of mechanical ventilator 
support are known to increase. Therefore the prevention of RSV 
infection in CHD patients is mandatory. The current standard for RSV 
prevention is immunoprophylaxis by palivizumab. Immunoprophylaxis 
is recommended monthly in hemodynamically significant CHD 
patients, up to 5 months. Motabizumab, a second generation drug and 
newly developing RSV vaccines are also expected to play a key role in 
RSV prevention in the future. The prophylaxis of RSV infection in CHD 
patients is cost-effective in both the medical aspect of the pa  tients as 
well as the socio-economic aspect. Therefore an effort to promote 
prevention should be made by not only the family of the patients but 
also by the government.              
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fatal outcome after RSV infection includes chronic lung disease, 
congenital heart disease (CHD), and prematurity
3). The indication 
and method of prevention for RSV infection in children with CHD 
will be discussed in this article.
CHD as a risk factor for serious RSV infection
Children diagnosed as CHD with RSV infection are known to 
have severe progress
2,3). The study for safety and efficacy of RSV 
Introduction
Respiratory syncytial virus (RSV) is a common pathogen in 
causing acute upper respiratory infection in all ages. RSV is a cause 
of frequent respiratory infection for children in particular. Most of 
the children are infected at least once by RSV by the age of 2 and 
symptomatic recurrent infections are also common even within one 
season
1). In children under the age of 2 with high risk factors, severe 
lower respiratory infection may develop
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prevention in CHD patients have been rapidly progressing since 
the development of palivizumab
4). Palivizumab (MEDI­493) 
is a humanized monoclonal antibody to F glycoprotein and has 
neutralizing and fusion inhibitory effect against RSV
5). Studies 
proving the efficacy of RSV prevention through palivizumab 
in CHD patients have been developing, and multinational, 
randomized, double­blind trials have proved its safety and efficacy
6). 
This study included patients who were 1 year old or younger, with 
hemodynamically significant CHD.  Hemodynamically significant 
CHD was defined as increased pulmonary blood flow with or 
without cyanosis, pulmonary venous congestion, pulmonary 
hypertension, and remaining residual hemodynamic abnormality 
after surgical correction, and these patients were recommended 
immunoprophylaxis of RSV infection. In a recently published study 
on RSV infection and hospitalization risk factors in CHD patients, 
Down syndrome and cardiomyopathy patients with RSV infection 
were also candidates who needed intensive care as well as the above 
mentioned patients
7). Through studies that have been conducted, 
the American Academy of Pediatrics (AAP) has included children 
with bronchopulmonary dysplasia, prematurity, hemodyanamically 
significant cyanotic and acyanotic CHD patients as high risk group 
for RSV infection, and expanded the age limit to 2 years of age or 
younger
2). Because hemodynamically significant CHD patients show 
severe progress, prevention of RSV infection is recommended.
Prevention for RSV infection
1. General prophylaxis
The primary prevention of RSV infection is minimizing exposure 
to RSV. Even after an exposure, minimizing recurrent exposure can 
reduce infection. Other preventive measures include the following: 1)
Reduce exposure to cigarette smoke 2) Restrict participation of child 
care in high risk patients during RSV season. 3) Encourage hand 
washing in all circumstances. Families with high risk patients who 
have older siblings are especially in need of intensive hand washing
8). 
Because RSV is highly contagious, special caution is needed for 
infants with CHD who are hospitalized
9). Therefore in high risk 
patients for RSV infection who are hospitalized need intense primary 
prevention, such as hand washing of medical staff, wearing a surgical 
mask and eye protection
10).  These efforts should be made more 
vigorously and thoroughly during RSV season.
2. Immunoprophylaxis
1) RSV immunoglobulin
Immunoglobulin for RSV (RSV­IVIG) was developed and first 
used in 1996 (RespiGam
Ⓡ, MedImmune, LLC, Gaithersburg, MD, 
USA). RSV­IVIG was first developed for preterm infants and it was 
contraindicated at first for patients diagnosed as CHD. Through 
controlled trial, hospitalization due to RSV infection was proven to 
decrease up to 41‒63% after use of RSV­IVIG
11). However, there 
was a possibility that the use of RSV­IVIG in children diagnosed as 
CHD increased the morbidity and mortality
12). Also, because RSV­
IVIG is a type of human blood product, there was a possibility of 
increased blood borne infection and interference of live vaccines such 
as measles, mumps, and rubella (MMR). Therefore the product was 
not used since the year 2003.
(1) Palivizumab
Palivizumab (Synagis
Ⓡ, MedImmune, LLC, Gaithersburg, 
MD, USA) was developed by grafting the six complementarity 
determining regions (CDRs) of mouse MAb to human frameworks
5). 
Palivizumab has received US FDA license in 1998, and it has been 
used to prevent serious lower respiratory tract infection caused by 
RSV infection ever since. The safety and efficacy was proven even for 
high­risk patients since then and currently, it is recognized as the gold 
standard in RSV prevention. Even in times when RSV­IVIG was 
being used, palivizumab was preferred because of the easy method 
of administration (intramuscular injection) and lower interference 
to MMR and varicella vaccine. Since RSV­IVIG is no longer 
available, palivizumab is the only licensed product for prevention 
of RSV infection. Infants diagnosed as CHD are considered as 
high­risk group for severe lower respiratory infection due to RSV 
infection, therefore immunoprophylaxis is recommended using 
palivizumab
2, 6,7,13­16).  Patients with hemodynamically significant 
cyanotic and acyanotic CHD should start administration of 
palivizumab before the RSV season starts. Commonly recommended 
administration dose for palivizumab is 15 mg/kg, intramuscularly 
once per month for a maximum of five doses
2,3). For most of the 
patients, the compliance under this schedule is tolerable. However, 
for the few non­compliant patients, home­based program for 
scheduled palivizumab administration may be helpful in reducing 
hospitalization caused by RSV infection
17). Hemodynamically 
significant CHD is described in Table 1
18). In these CHD infants 
categorized as high­risk group for RSV infection, if RSV prevention 
is not conducted effectively, mortality after hospitalization is known 
to increase
3). Particularly in these vulnerable infants who are less 
than 6 months old, the result of RSV infection is more catastrophic. 
These patients are more prone to hospitalization in the intensive care 
unit and they have higher possibility of ventilator care
19). The blood 
level of palivizumab after operation under cardiopulmonary bypass 
may drop by 58%, therefore CHD patients who need continuous 
prevention for RSV needs to administer palivizumab (15 mg/kg) 
soon after operation
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effectiveness of palivizumab for RSV infection in CHD patients 
has been pro  ven
4). In this study, patients who were administered 
palivizumab were hospitalized less often (5.3 versus 9.3%), were 
in need of oxygen administration less often (178 versus 658), and 
the total of hospitalization days were reduced (367 versus 876). 
Therefore, the use of palivizumab in prevention of RSV infection in 
CHD patients can be cost­effective in both the medical aspect of the 
patients as well as the socio­economic aspect
20­22). Although there are 
many studies reporting the advantages in socio­economic aspects 
after prophylaxis of RSV infection in CHD patients under the age of 
2 years, Korean medical insurance restricts the use of palivizumab to 
infants of hemodynamically significant CHD patients under the age 
of 1 year, unfortunately. Further studies and proposals in this matter 
are imminent. Complications after administration of palivizumab are 
very rare (<1 per 100,000 recipients), but there was a report of severe 
hypersensitivity
18). However, in a study reporting on the safety of 
palivizumab, there were no significant complications reported in the 
2 years that palivizumab was administered, which may prove that it is 
safe to use
23,24). In some studies, there were reports on RSV infection 
resistant to palivizumab
25). However, there was a report observing 
458 infants who were administered with palivizumab without any 
mutation, which may also prove that palivizumab is effective in 
RSV infection prophylaxis without much complication
26). Recently, 
the idea that palivizumab can be used not only for prophylaxis but 
also for treatment has been mentioned. However, further study 
for treatment effect of palivizumab to RSV in a large population is 
warranted
27,28).
(2) Motavizumab
Motavizumab (MEDI­524, Numax
Ⓡ, MedImmune, LLC, 
Gaithersburg, MD, USA) is a second generation monoclonal 
antibody for RSV. It is known to be more potent than palivizumab to 
RSV infection in high­risk patients. Motavizumab has passed the US 
FDA biologic license application in January of 2008 and is under a 
large scale clinical study
29,30).
2) RSV vaccines
Vaccination for RSV infection has not yet been developed. Theo­
retically, vaccination is a more effective long term preventive method 
than passive immunization such as palivizumab. Therefore there were 
numerous efforts trying to develop live attenuated, viral and bacterial 
vectored, and adjuvant subunit vaccines
31­33). However, development 
of effective RSV vaccines is not fulfilled even under these massive 
efforts. The interest in developing RSV vaccination is continuously 
increasing, and recently acquiring immunity of RSV using mu­
cosal and systemic immune response by nanoparticle vaccine is 
under study
34). However, there are many remaining limitations in 
developing an effective and safe RSV vaccine
35,36).
Conclusion
Patients, under the age of 2 years, diagnosed as hemodynamically 
significant CHD are high­risk group for serious RSV infection. 
Immunoprophylaxis in these high­risk patients are highly recom­
mended. The proven safe recommended administration dose for 
immunoprophylaxis of RSV infection is injecting 15mg/kg of 
palivizumab, intramuscularly once per month for a maximum of 
five doses. Motavizumab as well as RSV vaccine, currently under 
development, may contribute to RSV prevention in the future.
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Table1. Respiratory Ryncytial Virus Immunoprophylaxis for Infants and 
Young Children with Congenital Heart Disease
Most likely to benefit 
 from immunoprophylaxis
Infants receiving medication to control heart 
failure
  Infants with moderate to severe pulmonary 
hypertension
Infants with cyanotic heart disease
Not indicated Infants with hemodynamically insignificant heart 
diseas:
Secundum atrial septal defect
Small ventricular septal defect
Pulmonic stenosis
Uncomplicated aortic stenosis
Mild coarctation of the aorta
Patent ductus arteriosus
Infants with lesions adequately corrected 
by surgery unless they continue to require 
medication
Infants with mild cardiomyopathy who are not 
receiving medical therapy
Adapted from: revised indications for the use of palivizumab and respiratory 
syncytial virus immune globulin intravenous for the prevention of respiratory 
syncytial virus infections. Pediatrics 2003;112:1442
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